1. Company Overview
AGS Health Limited is a technology-enabled healthcare Revenue Cycle Management (RCM) company serving healthcare providers in the United States. The company combines AI, analytics, automation and global delivery capabilities to help hospitals and health systems manage patient access, coding, billing, claims, collections and revenue leakage.
AGS was incorporated on 12 November 2010 and is headquartered operationally across the U.S. and India, with its registered/corporate office in Chennai. The company has evolved from a healthcare BPO/medical-transcription business into a technology-led end-to-end RCM platform.
| Particular | Details |
|---|---|
| Company | AGS Health Limited |
| CIN | U72200TN2010PLC078062 |
| Incorporated | 12 November 2010 |
| Status | Unlisted Public Company |
| Registered Office | Chennai, Tamil Nadu |
| Global HQ | Washington, D.C., USA |
| Industry | Healthcare Technology / RCM |
| Core Market | United States |
| Promoter | BCP Asia II Topco VIII Pte. Ltd. |
| Current Owner | Blackstone |
| Employees | 15,895 as of FY26 |
| Global Delivery Sites | 10 |
| Customers | 149 |
| Hospital/Health-System Customers | 82 |
The latest SEBI filing identifies BCP Asia II Topco VIII Pte. Ltd. as the promoter, holding 98.54% of AGS Health before the proposed IPO.
Official website: AGS Health
SEBI IPO filing: AGS Health UDRHP – SEBI
2. What Does AGS Health Do?
AGS Health provides outsourced and technology-enabled services that help U.S. healthcare providers convert patient activity into collected revenue.
The company’s platform covers approximately 80% of the total RCM value chain, according to the company’s UDRHP citing the Zinnov Report.
Front-End Revenue Optimization
Services include:
- Patient access
- Eligibility and insurance verification
- Financial clearance
- Prior authorization
- Patient financial engagement
- Provider enrollment and credentialing
Mid-Cycle Revenue Optimization
This includes:
- Care management
- Medical coding
- Clinical documentation
- Revenue integrity
- Coding audit
- Compliance solutions
Back-End Revenue Optimization
AGS supports:
- Claims processing
- Claims posting
- Denial management
- Underpayment recovery
- Accounts receivable follow-up
- Collections
- Patient billing
These capabilities allow AGS to participate across the healthcare provider’s revenue cycle rather than focusing on only one outsourcing activity.
3. Technology & AI Platform
Technology is increasingly central to AGS Health’s business model.
The company has developed an AI-enabled platform covering areas such as:
- Computer-assisted coding
- Clinical documentation improvement
- Coding audit
- Revenue-cycle automation
- Intelligent authorization
- Autonomous coding
- Analytics
- Workflow automation
AGS launched its broader AI platform in 2022 and subsequently expanded its capabilities through acquisitions and product development.
The company’s latest corporate information describes AGS as a technology-first RCM provider, combining AI-driven solutions, data analytics and specialized global delivery capabilities.
4. Customer Base
AGS Health primarily serves U.S.-based healthcare organizations, including:
- Large health systems
- Hospitals
- Integrated delivery networks
- Physician groups
- Specialty healthcare providers
As of FY26, the company reported:
| Customer Metric | FY26 |
|---|---|
| Total Customers | 149 |
| Hospital / Health-System Customers | 82 |
| Customers generating >$1M revenue | 30 |
| Global Employees | 15,895 |
| Global Delivery Sites | 10 |
The company states that its customers include major U.S. healthcare organizations and that it served 11 of the top 20 U.S. hospitals as of March 2026.
5. Customer Concentration
Customer concentration is an important factor to monitor.
On the company’s reported basis, the top five customers accounted for 51.82% of FY26 revenue. On a pro-forma basis, the corresponding figure was 40.46%.
The top 10 customers represented 68.56% of FY26 revenue on the reported basis.
This means customer retention and expansion within large healthcare accounts are important drivers of AGS Health’s financial performance.
The company also reports long customer relationships: the average tenure of its top five customers was approximately 8.08 years in FY26.
6. Financial Performance
The latest SEBI UDRHP provides restated financial information through FY26.
Consolidated FY26 vs Earlier Standalone Years
| ₹ Crore | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue from Operations | 988.97 | 1,194.89 | 2,041.42 |
| EBITDA | 213.02 | 318.37 | 780.17 |
| EBITDA Margin | 21.54% | 26.64% | 38.22% |
| Profit After Tax | 115.64 | 142.93 | 206.95 |
| PAT Margin | 11.69% | 11.96% | 10.14% |
| Net Worth | 511.62 | 653.61 | 4,551.61 |
| Borrowings | Nil | Nil | 4,238.81 |
FY26 revenue from operations increased to approximately ₹2,041 crore, while EBITDA reached approximately ₹780 crore. The company reported FY26 profit of approximately ₹207 crore.
The FY26 revenue growth was approximately 70.85% on the reported consolidated basis. EBITDA margin increased substantially to 38.22%, compared with 26.64% in FY25.
Important Financial Point
FY26 numbers reflect the company’s post-acquisition/consolidated structure, so directly comparing them with earlier standalone figures can be misleading.
The UDRHP separately presents pro-forma financial information:
| ₹ Crore | FY24 Pro Forma | FY25 Pro Forma | FY26 |
|---|---|---|---|
| Revenue | 1,378.21 | 1,779.94 | 2,164.36 |
| EBITDA | 408.79 | 628.98 | 780.15 |
| EBITDA Margin | 29.66% | 35.34% | 36.05% |
| PAT | -345.52 | -275.99 | -141.04 |
The pro-forma figures incorporate the relevant acquisition structure and therefore provide a different view from the issuer’s reported consolidated numbers.
7. Profitability
One of the notable changes in AGS Health’s financial profile has been the expansion in EBITDA margin.
Reported EBITDA margin:
- FY24: 21.54%
- FY25: 26.64%
- FY26: 38.22%
The company attributes its business model to a combination of technology, automation, specialized healthcare expertise and global delivery capabilities.
FY26 adjusted profit was approximately ₹349.27 crore, compared with reported PAT of ₹206.95 crore. The difference reflects adjustments including exceptional items and acquisition-related amortisation.
8. U.S. Revenue Cycle Management Market
The company operates in a large and growing U.S. healthcare-services market.
According to the Zinnov Report cited in the UDRHP:
- U.S. healthcare expenditure in 2025: approximately $5.6 trillion
- U.S. RCM spend in 2025: approximately $234.5 billion
- RCM market in 2020: approximately $158.4 billion
- Estimated RCM market in 2030: approximately $329.8 billion
- 2025–2030 estimated CAGR: 7.1%
The company identifies rising claims complexity, higher denial rates, administrative intensity and increased adoption of outsourced technology-enabled RCM as market drivers.
9. Blackstone Acquisition
A major development for AGS Health was its acquisition by Blackstone.
EQT/Baring Private Equity Asia had acquired a majority stake in AGS Health in 2019. Blackstone subsequently acquired the company in 2025. Public transaction reports placed the deal value at around $1.4 billion.
The transaction brought AGS under Blackstone ownership and was followed by preparations for an Indian public listing.
AGS Health’s current corporate information identifies Blackstone as its 2025 owner, with Baring Private Equity Asia being the previous financial sponsor.
10. IPO Plans – Major Development
AGS Health is now on the IPO path
This is an important change from the company’s earlier unlisted status.
AGS Health confidentially filed its IPO documents with SEBI in 2026. SEBI’s processing-status documents show AGS Health’s IPO filing as a Fresh + OFS issue.
SEBI subsequently published the company’s Updated Draft Red Herring Prospectus (UDRHP) in August 2026.
Proposed IPO Size
The August 2026 UDRHP proposes:
| Component | Proposed Size |
|---|---|
| Fresh Issue | Up to ₹1,800 Cr |
| Offer for Sale | Up to ₹3,000 Cr |
| Total IPO | Up to ₹4,800 Cr |
| Possible Pre-IPO Placement | Up to ₹360 Cr |
The OFS is proposed to be sold by BCP Asia II Topco VIII Pte. Ltd., the promoter entity.
Use of Fresh Issue Proceeds
Approximately ₹1,600 crore from the fresh issue is proposed to be used for repayment/prepayment of borrowings of AGS Health’s indirect subsidiaries.
The balance is proposed for general corporate purposes, subject to the final offer documents.
IPO Listing
The proposed shares are intended to be listed on:
- BSE
- NSE
The August 2026 UDRHP does not yet provide the final price band or bid dates; these remain to be finalized in subsequent offer documents.
11. Proposed Valuation
Earlier reporting around the confidential IPO filing indicated a potential valuation of approximately $3 billion. This was reported market information rather than a final IPO valuation.
The August 2026 UDRHP itself states that the floor price, cap price and offer price had not yet been finalized. Therefore, investors should not treat the reported $3 billion figure as the final IPO valuation.
The UDRHP does disclose the promoter’s weighted average acquisition cost of ₹204.04 per equity share.
12. Shareholding
Before the IPO, the promoter BCP Asia II Topco VIII Pte. Ltd. holds:
383.49 million shares = 98.54%
The remaining shares are primarily held by existing/director/employee-related shareholders listed in the UDRHP.
The proposed OFS will therefore provide an opportunity for the Blackstone-controlled promoter entity to monetize part of its investment while the fresh issue provides capital to the company/group for debt reduction and corporate purposes.
13. Major Strategic Developments
Acquisition of EZDI
AGS acquired EZDI in 2021, adding healthcare technology and clinical documentation capabilities to its platform.
Availity Patient Access Business
In 2023, AGS acquired Availity’s India-based patient-access outsourcing business and its Intelligent Authorization technology, expanding its patient-access and prior-authorization capabilities.
Philippines Expansion
AGS expanded into the Philippines in 2023 to strengthen business continuity and add capabilities across patient outreach, clinical services and accounts receivable.
Mexico Expansion
The company established a near-shore delivery center in Mexico in 2025, adding to its global delivery model.
14. Key Growth Drivers
1. U.S. healthcare spending
Large healthcare expenditure creates a substantial addressable RCM market.
2. Increasing complexity of healthcare billing
More complex reimbursement models and claims can increase demand for specialized RCM services.
3. AI and automation
Automation can potentially improve coding, authorization, denial management and revenue-cycle workflows.
4. Cross-selling
AGS can expand revenue from existing healthcare customers by adding services across different stages of the RCM cycle.
5. Global delivery model
India, Philippines and Mexico provide a distributed delivery structure supporting cost-efficient service delivery.
6. IPO-led deleveraging
The proposed ₹1,600 crore debt repayment allocation could reduce borrowings at the relevant subsidiaries if the issue proceeds as proposed.
15. Key Risks
Customer concentration
The top five customers represented 51.82% of FY26 reported revenue, creating exposure to the loss or downsizing of major accounts.
High leverage after acquisition
FY26 consolidated borrowings stood at approximately ₹4,239 crore, while net debt was approximately ₹3,814 crore.
U.S. healthcare dependence
The company is heavily focused on the U.S. healthcare market, so changes in reimbursement, regulation, healthcare-provider economics or outsourcing trends can affect demand.
Technology competition
AGS competes with other RCM outsourcing and healthcare-technology providers, including companies developing increasingly automated AI-based solutions.
Employee attrition
The company reported a global voluntary attrition rate of approximately 23.27% in FY26, making talent retention an important operating factor.
IPO valuation risk
The final IPO price has not yet been determined. The valuation investors ultimately pay will be important when comparing AGS Health with listed RCM/healthcare-technology peers.
16. AGS Health vs Traditional Healthcare BPO
AGS Health’s business model has increasingly shifted toward technology-enabled RCM rather than traditional manpower-based outsourcing.
Traditional BPO → Technology-enabled RCM → AI-driven Healthcare Revenue Platform
This transition is visible in the company’s increasing focus on:
- AI
- SaaS
- Automation
- Analytics
- Intelligent authorization
- Autonomous coding
- Revenue-cycle intelligence
The company reported that 14.50% of FY26 revenue came from customers using both SaaS solutions and technology-enabled services.
17. Unlisted / Pre-IPO Status
AGS Health is currently in the transition from an unlisted company to a proposed listed company.
As of the latest August 2026 UDRHP:
- IPO documents filed: Yes
- SEBI observations/approval: Yes
- Updated DRHP/UDRHP filed: Yes
- Proposed issue: ₹4,800 Cr
- Fresh issue: ₹1,800 Cr
- OFS: ₹3,000 Cr
- Price band: Not announced
- IPO opening date: Not announced
- Listing date: Not announced
- Proposed exchanges: NSE & BSE
SEBI’s August 2026 filing confirms that the final price and bid/offer dates were still to be filled in subsequent documents.
18. UnlistedCart Takeaway
AGS Health represents a different type of healthcare opportunity: it is not a hospital or pharmaceutical company, but a technology-enabled healthcare revenue-cycle platform focused primarily on the U.S. market.
The company has scaled to ₹2,041 crore of FY26 revenue, ₹780 crore of EBITDA and ₹207 crore of reported profit, alongside a global workforce of nearly 15,900 employees and 149 customers.
The most significant development is its proposed ₹4,800 crore IPO, comprising ₹1,800 crore fresh issue and ₹3,000 crore OFS. The fresh capital is primarily intended for debt repayment at indirect subsidiaries, while the OFS provides an exit/liquidity opportunity for the Blackstone-controlled promoter.
For investors tracking the company in the pre-IPO/unlisted market, the key variables to watch are final IPO valuation, price band, post-IPO promoter holding, debt reduction, customer concentration, EBITDA sustainability and the premium/discount between any pre-IPO transaction price and the eventual IPO price.
Important Sources
- AGS Health – Official Website
- AGS Health – Company Information
- SEBI – AGS Health UDRHP
- SEBI – AGS Health Abridged Prospectus
- Reuters – AGS Health ₹4,800 Cr IPO Update
- Moneycontrol – AGS Health Updated DRHP
Disclaimer: This report is for informational and educational purposes only and should not be considered investment advice. AGS Health is currently in the IPO process, and the final offer price, price band, issue structure, subscription dates and listing date may change. Pre-IPO/unlisted transactions can involve significant liquidity, valuation and transfer risks. Investors should read the final RHP/prospectus and independently verify all financial and corporate information before investing.
For more such unlisted stocks visit UnlistedCart – Unlisted Shares
